Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib- melphalanprednisone (VMP) in untreated multiple myeloma patients with renal impairment

Fortunato Morabito, Massimo Gentile, Carla Mazzone, Davide Rossi, Francesco Di Raimondo, Sara Bringhen, Roberto Ria, Massimo Offidani, Francesca Patriarca, Chiara Nozzoli, Maria Teresa Petrucci, Giulia Benevolo, Iolanda Vincelli, Tommasina Guglielmelli, Mariella Grasso, Roberto Marasca, Luca Baldini, Vittorio Montefusco, Pellegrino Musto, Nicola CascavillaIgnazio Majolino, Caterina Musolino, Michele Cavo, Mario Boccadoro, Antonio Palumbo

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib- melphalanprednisone (VMP) in untreated multiple myeloma patients with renal impairment'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds